Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human Flag-tagged RIG-I lactylation IP-MS in HEK293T

ABSTRACT: The PARP inhibitor olaparib is widely used in cancer but is underused in treating lung adenocarcinoma (LUAD). Our initial analysis revealed that RIG-I, which is typically found in the cytoplasm and activates innate immunity, is linked to LUAD outcome. Here, we discovered that RIG-I undergoes lactylation, with the acetyltransferase PCAF serving as the lactylation writer. Treatment with the lactate transporter inhibitor syrosingopine prevents the efflux of lactic acid from cancer cells, increasing intracellular lactic acid, promoting RIG-I lactylation, and enhancing its interaction with the nuclear transport protein importin 8. The augmented interaction facilitates the nuclear translocation of RIG-I, diminishing PARP1 activity and enhancing the therapeutic effects when combined with olaparib. This synergy disrupts PARP1-mediated DNA repair mechanisms, increasing drug sensitivity and inhibiting tumor growth. The combination of olaparib and syrosingopine demonstrates better therapeutic efficacy than olaparib monotherapy in LUAD, providing a promising strategy for future LUAD treatments.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Lung Adenocarcinoma

SUBMITTER: yulin li

LAB HEAD: Yulin Li

PROVIDER: PXD058596 | Pride | 2025-12-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	LYL_20210826_RIg-I.mzML	Mzml
	LYL_20210826_RIg-I.mzid.gz	Mzid
	LYL_20210826_RIg-I.pdResult	Other
	LYL_20210826_RIg-I.raw	Raw

Items per page:

1 - 4 of 4

Similar Datasets

Human Flag-tagged RIG-I IP-MS in HEK293T

Project description:nevaeh: The PARP inhibitor olaparib is widely used in cancer but is underused in treating lung adenocarcinoma (LUAD). Our initial analysis revealed that RIG-I, which is typically found in the cytoplasm and activates innate immunity, is linked to LUAD outcome. Here, we discovered that RIG-I undergoes lactylation, with the acetyltransferase PCAF serving as the lactylation writer. Treatment with the lactate transporter inhibitor syrosingopine prevents the efflux of lactic acid from cancer cells, increasing intracellular lactic acid, promoting RIG-I lactylation, and enhancing its interaction with the nuclear transport protein importin 8. The augmented interaction facilitates the nuclear translocation of RIG-I, diminishing PARP1 activity and enhancing the therapeutic effects when combined with olaparib. This synergy disrupts PARP1-mediated DNA repair mechanisms, increasing drug sensitivity and inhibiting tumor growth. The combination of olaparib and syrosingopine demonstrates better therapeutic efficacy than olaparib monotherapy in LUAD, providing a promising strategy for future LUAD treatments. nevaeh: HEK293T cells were transfected with Flag-RIG-I for 48 h, lysed in NP-40 buffer, and sonicated using a JY92-II sonicator. The supernatant was first incubated overnight with an anti-Flag conjugated with beads (Sigma, A2220) after being denatured. Following centrifugation at 3,000 rpm (4°C for 5 min), the supernatants were completely removed, and 60 μL of Flag–peptide was added to competitively bind to the beads. RIG-I protein was released, precipitated using Trichloroacetic acid (TCA), and subjected to mass spectrometry analysis for lactylation.

2025-12-10 | PXD058597 | Pride

Type I interferon/STAT1 signaling negative feedback regulates UBE2M-mediated antiviral innate immunity

Project description:To identify potential proteins involved in RIG-I regulation, we pulled down RIG-I from HEK293T or NIH-3T3 cells overexpressing RIG-I, and the RIG-I-bound proteins were then analyzed by mass spectrometry (MS).

2023-01-30 | PXD039071 | Pride

Identification of lysine sites in RIG-I ubiquitinated by RNF167 through mass spectrometry analysis

Project description:To identify RNF167-catalyzed ubiquitinated peptides of RIG-I

2025-02-07 | PXD060570 | Pride

Identification of avian RIG-I responsive genes during influenza infection

Project description:Transcriptional profiling of chicken embryonic fibroblasts (DF-1 cells) comparing the effects of chicken cells transfected with duck RIG-I compared to empty-vector transfected cells following with low or highly pathogenic avian influenza. Goal was to determine the effects of duck RIG-I on influenza-induced immune gene expression. Two-condition experiment. Biological replicates for low pathogenic avian influenza infection: 3 empty-vector transfected replicates, 3 RIG-I transfected replicates. Biological replicates for highly pathogenic influenza infection: 2 empty-vector transfected replicates, 2 RIG-I transfected replicates.

2012-12-12 | E-GEOD-29596 | biostudies-arrayexpress

Effect of PARP1 inhibition on transcription in MCF7 cells

Project description:Analysis of the role of PARP1 in gene transcription in MCF7 cells under non-stress conditions. The hypothesis was that PARP1 activity in MCF7 cells plays a role in gene transcription. The results indicate that PARP1 inhibition does not significantly affect transcription after 6 hours of treatment. Total RNA was collected from MCF7 cells that had been treated with ABT-888, PJ34, Olaparib, or DMSO for 6 hours.

2014-09-04 | E-GEOD-56400 | biostudies-arrayexpress

3' UTR RNA-sequencing of human lung adenocarcinoma cell lines PC9 and A549 treated with RIG-I agonist IVT4/unspecific control IVT-GAC

Project description:The cell lines were treated with RIG-I agonist IVT4 or unspecific control IVT-GAC for 8h and then harvested for 3' UTR RNA-seq analysis

2021-08-09 | E-MTAB-10802 | biostudies-arrayexpress

Blocking Fra-1 sensitizes triple-negative breast cancer to olaparib

Project description:Fra-1 (FOSL1) is overexpressed in triple-negative breast cancer (TNBC). Fra-1 is a member of the activator protein 1 (AP-1) transcription factor complex, which plays crucial roles in tumor progression and treatment resistance. We have previously identified 118 proteins that interact with endogenous chromatin-bound Fra-1 in TNBC cells in a large screen, and these included PARP1(Poly (ADP-ribose) polymerase 1). PARP1 inhibitor olaparib is currently in clinical use for treatment of BRCA-mutated TNBC breast cancer. Here, we demonstrate that this interaction impacts the efficacy of olaparib treatment. We corroborate that PARP1 interacts with Fra-1, and we show that PARP1 downregulates Fra-1 and consequently reduces AP-1 transcriptional activity. Inhibition of PARP1, on the other hand, increases Fra-1 levels and enhances its transcriptional activity, which in turn can increase treatment resistance. However, by inhibiting Fra-1, we found that TNBC cells became sensitized to olaparib treatment. We compared Fra-1 chromatin binding sites with the Fra-1 and PARP1 regulated transcriptomes, and found that a large fraction of PARP1-regulated genes was dependent on Fra-1. We further show that PARP1 protein levels significantly correlate with Fra-1 in clinical breast cancer tumors, and we identify that high PARP1 expression is indicative of a poor clinical outcome in breast cancer patients overall, but not in basal-like tumors. In conclusion, by exploring the functionality of the Fra-1 and PARP1 interaction, we propose that targeting Fra-1 could serve as a therapeutic approach to improve olaparib treatment outcome for TNBC patients.

2022-04-21 | GSE149621 | GEO

PARP1- and CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription

Project description:Transcriptionally active and inactive chromatin domains tend to segregate into separate sub-nuclear compartments to maintain stable expression patterns. However, we have uncovered here an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs). The interactome is regulated by PARP1 and its co-factor, CTCF, which not only mediate chromatin fiber interactions, but also promote the recruitment of circadian genes to the lamina. Synchronization of circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by Olaparib or down-regulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription. PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina thus mediate circadian transcriptional plasticity. ChIP-Seq for H3k9me2 in HCT116 colon cancer cells (2 replicates)

2015-08-27 | E-GEOD-58534 | biostudies-arrayexpress

The mass spectrometry analysis detected differences in protein lactylation in B16 cells after lactic acid treatment.

Project description:In this experiment, we treated the B16 cell line with lactic acid and performed peptide immunoprecipitation using anti-lactylation antibodies. We then detected the overall lactylation modifications of intracellular proteins after lactic acid treatment using mass spectrometry.

2025-07-21 | PXD060840 | Pride

PARP1- and CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription

Project description:Transcriptionally active and inactive chromatin domains tend to segregate into separate sub-nuclear compartments to maintain stable expression patterns. However, we have uncovered here an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs). The interactome is regulated by PARP1 and its co-factor, CTCF, which not only mediate chromatin fiber interactions, but also promote the recruitment of circadian genes to the lamina. Synchronization of circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by Olaparib or down-regulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription. PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina thus mediate circadian transcriptional plasticity. Examination of intra- and interchromosomal interactions in human embryonic stem cells (HESCs) and derived embryoid bodies (HEBs) generated by 4C-seq, as described in (Zhao et al., 2006), using Illumina Genome Analyzer II and Illumina MiSeq. Examination of mRNA profiles in HESCs and derived HEBs generated by deep sequencing, in duplicate, using Illumina HiSeq 2500.

2015-08-27 | E-GEOD-26880 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data